R&D:Designs and produces microbial antigens by recombinant technology, individual antigens are well-defined and thoroughly investigated for their biological properties. The vaccines will be adjuvanted with conventional adjuvans as well as with a pattented nano adjuvant.
Lazarettgasse 19
1090 Vienna
Vienna
Contact: Martha Eibl (CEO)
Telephone: +43 (1) 4081091
Email: office@biomed-research.at